Profile data is unavailable for this security.
About the company
Kyowa Kirin Co Ltd, formerly Kyowa Hakko Kirin Co Ltd is a Japan-based company engaged in the manufacture and sale of prescription pharmaceuticals. The Company operates in a single pharmaceuticals business segment. The Company engages in the research, development, manufacture, sale, and import & export of prescription pharmaceuticals. The Company has POTELLIGENT technology for producing active antibodies. The Company provides products include Poteligeo for the treatment of mycosis fungoides and sezary syndrome, and Crysvita for the treatment of X chromosome-linked hypophosphatemia. Besides, the Company also develops, manufactures, and markets biosimilar drugs, and engages in contracting, wholesale and retail business, and insurance agency business. The Company operates in Japan and overseas.
- Revenue in JPY (TTM)498.98bn
- Net income in JPY83.53bn
- Incorporated1949
- Employees5.97k
- LocationKyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
- Phone+81 352057200
- Fax+81 352057182
- Websitehttps://www.kyowakirin.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nippon Shinyaku Co., Ltd. | 154.27bn | 26.05bn | 291.82bn | 2.21k | 10.74 | 1.19 | 9.24 | 1.89 | 386.74 | 386.74 | 2,290.53 | 3,486.81 | 0.5956 | 1.29 | 3.36 | 69,711,700.00 | 10.06 | 10.45 | 11.39 | 12.31 | 67.69 | 61.27 | 16.89 | 16.47 | 4.22 | -- | 0.0107 | 32.62 | 2.83 | 5.26 | 13.32 | 9.66 | 45.93 | 12.12 |
| Hisamitsu Pharmaceutical Co Inc | 150.19bn | 14.65bn | 364.85bn | 2.76k | 21.95 | 1.15 | 17.50 | 2.43 | 195.20 | 195.20 | 1,996.17 | 3,730.09 | 0.4323 | 3.01 | 3.22 | 54,434,580.00 | 4.36 | 4.22 | 5.25 | 4.82 | 56.42 | 58.62 | 10.10 | 10.03 | 3.14 | -- | 0.004 | 53.05 | 10.42 | -0.2385 | 18.97 | -6.17 | 28.90 | 0.5989 |
| Tsumura & Co | 164.61bn | 25.20bn | 370.21bn | 4.14k | 14.53 | 1.24 | 9.66 | 2.25 | 331.93 | 331.93 | 2,167.87 | 3,875.47 | 0.3783 | 0.6916 | 2.48 | 39,781,050.00 | 6.23 | 4.81 | 7.63 | 5.89 | 48.76 | 50.98 | 16.48 | 12.65 | 3.04 | -- | 0.1806 | 32.16 | 7.71 | 4.52 | 1.37 | 2.74 | 17.54 | 5.84 |
| Santen Pharmaceutical Co Ltd | 302.56bn | 26.13bn | 605.73bn | 3.74k | 22.65 | 2.01 | 13.64 | 2.00 | 73.46 | 73.46 | 846.14 | 827.65 | 0.7238 | 2.58 | 3.68 | 80,812,770.00 | 6.25 | 3.31 | 7.77 | 4.10 | 57.92 | 59.73 | 8.64 | 5.21 | 1.97 | 5.38 | 0.1639 | 82.21 | 8.22 | 5.23 | 278.09 | -3.58 | 5.10 | 4.88 |
| Rohto Pharmaceutical Co Ltd | 282.05bn | 27.26bn | 648.31bn | 7.26k | 23.03 | 2.47 | 17.82 | 2.30 | 119.22 | 119.22 | 1,233.69 | 1,109.16 | 0.759 | 2.18 | 4.12 | 38,855,630.00 | 7.37 | 8.54 | 10.29 | 11.79 | 57.38 | 58.59 | 9.71 | 10.30 | 1.29 | -- | 0.1442 | 19.39 | 13.48 | 8.09 | 17.28 | 25.85 | 5.20 | 18.61 |
| Ono Pharmaceutical Co Ltd | 484.30bn | 95.13bn | 870.97bn | 3.85k | 8.68 | 1.05 | 7.69 | 1.80 | 201.26 | 201.26 | 1,026.05 | 1,665.85 | 0.4987 | 2.37 | 3.47 | 125,694,000.00 | 9.80 | 11.95 | 11.16 | 13.73 | 75.38 | 74.11 | 19.65 | 23.89 | 2.80 | -- | 0.1702 | 32.25 | 12.41 | 11.73 | 13.53 | 19.95 | -6.79 | 12.20 |
| Kyowa Kirin Co Ltd | 498.98bn | 83.53bn | 1.34tn | 5.97k | 16.25 | 1.60 | 12.39 | 2.68 | 156.64 | 156.64 | 936.10 | 1,591.79 | 0.4878 | 1.78 | 3.92 | 83,524,780.00 | 8.17 | 6.28 | 9.50 | 7.08 | 74.30 | 75.45 | 16.74 | 14.96 | 3.06 | -- | 0.0276 | 47.25 | 11.01 | 10.25 | 51.55 | 10.52 | 10.28 | 9.86 |
| Eisai Co Ltd | 753.22bn | 40.97bn | 1.37tn | 11.07k | 32.22 | 1.59 | 16.59 | 1.82 | 143.36 | 143.36 | 2,634.81 | 2,905.11 | 0.5673 | 0.8933 | 3.89 | 68,060,180.00 | 3.21 | 5.29 | 4.32 | 7.16 | 79.12 | 76.91 | 5.67 | 8.68 | 1.50 | -- | 0.1781 | 74.13 | -0.3561 | 2.90 | -23.50 | -7.72 | -2.11 | 1.30 |
| Shionogi & Co Ltd | 418.51bn | 154.57bn | 1.83tn | 4.96k | 11.39 | 1.35 | 10.59 | 4.38 | 180.74 | 180.74 | 489.15 | 1,519.70 | 0.292 | 0.9189 | 2.94 | 84,393,830.00 | 10.69 | 12.57 | 11.94 | 14.24 | 85.70 | 84.43 | 36.62 | 37.91 | 6.48 | -- | 0.0088 | 26.77 | 1.97 | 3.41 | -12.40 | 3.38 | 2.17 | 11.22 |
| Astellas Pharma Inc | 1.77tn | 54.75bn | 2.84tn | 14.75k | 51.68 | 1.84 | 11.35 | 1.61 | 30.42 | 30.42 | 986.34 | 854.61 | 0.5060 | 1.36 | 3.39 | 120,113,500.00 | 1.56 | 4.59 | 2.31 | 6.61 | 81.78 | 80.53 | 3.09 | 7.98 | 0.8623 | 15.32 | 0.3774 | 86.61 | 5.60 | 4.19 | -82.73 | -40.17 | 9.62 | 13.00 |
| Otsuka Holdings Co Ltd | 2.27tn | 151.58bn | 4.99tn | 34.39k | 32.03 | 1.93 | 18.98 | 2.20 | 279.51 | 279.51 | 4,183.34 | 4,641.15 | 0.647 | 2.40 | 4.68 | 65,998,690.00 | 4.42 | 4.80 | 5.59 | 5.88 | 71.42 | 68.21 | 6.84 | 8.36 | 1.53 | -- | 0.1173 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| Takeda Pharmaceutical Co Ltd | 4.55tn | 289.99bn | 6.56tn | 49.28k | 22.66 | 0.9439 | 6.25 | 1.44 | 181.90 | 181.90 | 2,862.68 | 4,365.91 | 0.3088 | 1.31 | 6.25 | 92,248,190.00 | 1.97 | 1.65 | 2.35 | 1.97 | 66.05 | 68.05 | 6.38 | 6.06 | 0.7739 | 3.08 | 0.4219 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
Data as of Nov 22 2024. Currency figures normalised to Kyowa Kirin Co Ltd's reporting currency: Japanese Yen JPY
12.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 07 Nov 2024 | 17.40m | 3.31% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 8.66m | 1.65% |
| Nikko Asset Management Co., Ltd.as of 08 Nov 2024 | 8.61m | 1.64% |
| Daiwa Asset Management Co. Ltd.as of 31 Oct 2024 | 8.04m | 1.53% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 5.82m | 1.11% |
| Goldman Sachs Asset Management Co., Ltd. (Japan)as of 30 Aug 2024 | 5.37m | 1.02% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 07 Nov 2024 | 4.57m | 0.87% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 4.49m | 0.85% |
| Geode Capital Management LLCas of 14 Nov 2024 | 2.51m | 0.48% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 2.30m | 0.44% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
